Celularity (CELU) Stock Price

Celularity Price

NASDAQ·CLOSED
1.16
​
Market closed

Revenue has compounded at 6.1% per year over the past 7 years to 26.55 M USD. Celularity's net margin stands at -345.8%, up from -469.3% several years earlier. Analysts set a median price target of 2.55 USD, implying 119.8% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Celularity stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity business model & stock analysis

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.

Frequently asked questions about Celularity

Analysts currently set an average price target of 2.55 USD for the Celularity stock (median: 2.55 USD), implying +119.8 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Celularity stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Celularity to generate revenue of 44.00 M USD and earnings per share of -2.75 USD.

Converted at the current exchange rate, the Celularity share trades at 1.03 EUR (1.16 USD).

The Celularity share (CELU) is listed on 1 stock exchanges, including: NASDAQ (CELU).

The expected revenue of Celularity is 44.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Celularity is -79.31 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Celularity is currently -0.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Celularity stock.

The price-to-sales ratio (P/S) of Celularity is currently 0.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Celularity stock.

The Eulerpool Quality Score for Celularity is 3/10.

The ISIN of Celularity is US1511902041. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Celularity is CELU. The ticker symbol is used to trade Celularity shares on the stock exchange.

Fair ValueTerminal
1.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
118,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 23, 2019
ISIN
US1511902041
Cusip
151190105
Market capitalization
33.45 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.42
P/Ee 2027
0.77
P/S
P/Se
0.76
EV/EBIT
—
P/B Ratio
3.79
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-3,233.53 %
Last updated Oct 20, 2026, 1:35 PM

Celularity Peer Group

Celularity Ticker

NASDAQ · CELU

All fundamentals and in-depth analysis of Celularity

Our stock analysis for Celularity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celularity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.